Talazoparib loaded solid lipid nanoparticles: Preparation, characterization and evaluation of the therapeutic efficacy in vitro

dc.contributor.authorEskiler, Gamze Güney
dc.contributor.authorDikmen, Gökhan
dc.contributor.buuauthorÇeçener, Gülşah
dc.contributor.buuauthorEgeli, Ünal
dc.contributor.buuauthorTunca, Berrin
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalıtr_TR
dc.contributor.orcid0000-0002-3820-424X
dc.contributor.orcid0000-0001-7904-883X
dc.contributor.orcid0000-0002-1619-6680
dc.contributor.researcheridAAP-9988-2020
dc.contributor.researcheridAAH-1420-2021
dc.contributor.researcheridABI-6078-2020
dc.contributor.scopusid6508156530
dc.contributor.scopusid55665145000
dc.contributor.scopusid6602965754
dc.date.accessioned2024-05-15T11:37:15Z
dc.date.available2024-05-15T11:37:15Z
dc.date.issued2019
dc.description.abstractObjective: In the present work, we report for the first time the therapeutic potential of talazoparib (BMN 673)-SLNs for the treatment of BRCA1 deficient Triple Negative Breast Cancer (TNBC). BMN 673-SLNs were produced by hot-homogenization technique and then characterized. Methods: The cytotoxic and apoptotic effects of BMN 673-SLNs compared with BMN 673 were determined on HCC1937BRCA1-/-, HCC1937-R resistant TNBC and MCF-10A control cell lines. BMN 673- SLNs were found to have reduced particle size (219.5 ± 1.45 nm) and thus more stable (-28.4 ± 2.52 mV) than BMN 673 (1652 ± 2.46 nm and -18.6 ± 0.45 mV) at 4ºC. Results: In vitro cell line studies demonstrated that BMN 673-SLNs showed significant cytotoxic effects on HCC1937 (29.8%) and HCC1937-R cells (35.7%) at 10 nM for 12 days compared with BMN 673 (HCC1937 cells: 34.0% and HCC1937-R cells: 93.8% at 10 nM for 12 days) (p<0.05). Additionally, BMN 673-SLNs (40.1%) reduced the toxicity of BMN 673 (53.1%) on MCF-10A control cells thanks to unique physical properties. Conclusion: The apoptotic rates in the 10 nM BMN 673-SLNs treatment (88.78% and 85.56%) for 12 days were significantly higher than those in 10 nM BMN 673 (82.6% and 25.86%) for 12 days in HCC1937 and HCC1937-R cells, respectively (p<0.01). Furthermore, these effects were consistent with the findings of colony formation, wound healing and calcein accumulation analysis. In conclusion, the therapeutic potential of BMN 673-SLNs provides a promising chemotherapeutic strategy for the treatment of drugresistant TNBC.en_US
dc.identifier.citationEskiler, G. G. vd. (2019). " Talazoparib loaded solid lipid nanoparticles: Preparation, characterization and evaluation of the therapeutic efficacy in vitro", 16(6), 511-529.en_US
dc.identifier.doihttps://doi.org/10.2174/1567201816666190515105532
dc.identifier.endpage529
dc.identifier.issn1567-2018
dc.identifier.issue6
dc.identifier.pubmed31113350
dc.identifier.scopus2-s2.0-85072849067
dc.identifier.startpage511
dc.identifier.urihttps://www.eurekaselect.com/article/98496
dc.identifier.urihttps://hdl.handle.net/11452/41441
dc.identifier.volume16
dc.identifier.wos000483386900004
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherBentham Science Publisheren_US
dc.relation.bapBUAP(T)-2015/1
dc.relation.collaborationYurt içitr_TR
dc.relation.journalCurrent Drug Deliveryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTriple negative breast cancer (TNBC)en_US
dc.subjectPARP inhibitorsen_US
dc.subjectTalazoparib (BMN 673)en_US
dc.subjectSolid lipid nanoparticles (SLNs)en_US
dc.subjectApoptosisen_US
dc.subjectCytotoxic effectsen_US
dc.subjectDrug-delivery-systemsen_US
dc.subjectInhiıbitor Bmn 673en_US
dc.subjectParp Inhibitoren_US
dc.subjectDNA-repairen_US
dc.subjectMultidrug-resistanceen_US
dc.subjectSynthetic lethalityen_US
dc.subjectHighly potenten_US
dc.subjectCanceren_US
dc.subjectCytotoxicityen_US
dc.subjectPaclitaxelen_US
dc.subject.meshAntineoplastic agentsen_US
dc.subject.meshApoptosisen_US
dc.subject.meshBRCA1 proteinen_US
dc.subject.meshCell proliferationen_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshDrug screening assays, antitumoren_US
dc.subject.meshLipidsen_US
dc.subject.meshNanoparticlesen_US
dc.subject.meshPhthalazinesen_US
dc.subject.meshStructure-activity relationshipen_US
dc.subject.meshTriple negative breast neoplasmsen_US
dc.subject.meshTumorcellsen_US
dc.subject.meshCultureden_US
dc.subject.meshFemaleen_US
dc.subject.scopusOlaparib; Ovarian Neoplasms; Homologous Recombinationen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.titleTalazoparib loaded solid lipid nanoparticles: Preparation, characterization and evaluation of the therapeutic efficacy in vitroen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: